Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/29/2025

Management of Patients with Coronary Stents Undergoing Non-Cardiac Surgery

Introduction to Dual Antiplatelet Therapy (DAPT)

  • The American College of Cardiology and the European Society of Cardiology recommend dual antiplatelet therapy (DAPT) for preventing stent thrombosis after percutaneous coronary intervention (PCI), but it must be balanced with the risk of perioperative bleeding in patients requiring non-cardiac surgery 1
  • Premature discontinuation of DAPT is a significant risk factor for stent thrombosis, with a risk of approximately 40% of myocardial infarction and death, according to the European Society of Cardiology 1

Risk Assessment and Management

  • The risk of thrombotic complications related to the stent is highest in the first 1-6 months after implantation, with a very high risk in patients with a drug-eluting stent placed only 2 months prior to surgery, as stated by the European Heart Journal and the American College of Cardiology 2, 3
  • The risk of bleeding varies by surgical procedure, with a moderate risk for laparoscopic cholecystectomy, according to the European Heart Journal 2

Antiplatelet Therapy Management

  • The American College of Cardiology recommends maintaining aspirin (75-100 mg/day) throughout the perioperative period 2
  • The European Heart Journal suggests suspending the P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) 5-7 days before surgery, depending on the specific medication, and restarting it as soon as possible after surgery, ideally within 24-48 hours, as recommended by the American College of Cardiology 2, 4

Multidisciplinary Approach and Bridging Therapy

  • A multidisciplinary approach, including the cardiologist, surgeon, and anesthesiologist, is recommended by the European Heart Journal 2
  • The American College of Cardiology suggests considering a bridging strategy with intravenous antiplatelet agents (tirofiban, eptifibatide) if the risk of bleeding is extremely high and surgery cannot be postponed 2

Postoperative Monitoring and Complications

  • Close monitoring of the patient in the immediate postoperative period is recommended to detect both hemorrhagic and ischemic complications, according to the European Heart Journal and the American College of Cardiology 1, 2
  • Never suspending both antiplatelet agents simultaneously in the first 6 months after stent placement, unless it is a life-threatening emergency, is advised by the American College of Cardiology 2

Dual Antiplatelet Therapy (DAPT) Duration

  • The optimal duration of DAPT depends on several factors, including post-PCI with stent placement, with a minimum of 1 month regardless of stent type, and a standard duration of 12 months for Acute Coronary Syndrome (ACS) patients, as recommended by the European Society of Cardiology 2
  • The type of stent (drug-eluting stent (DES) or bare metal stent (BMS)) and the clinical presentation at the time of stenting (ACS or Stable Coronary Artery Disease (SCAD)) guide the DAPT duration, with DES typically requiring 12 months of DAPT and BMS requiring 1-6 months, according to the European Society of Cardiology guidelines 2

Antiplatelet Therapy Recommendations

  • Aspirin (75-100 mg daily) plus a P2Y12 inhibitor (ticagrelor, prasugrel, or clopidogrel) is recommended as first-line therapy, with aspirin continued indefinitely after stent placement, as recommended by the European Society of Cardiology 2
  • Low-dose aspirin (75-100 mg) is recommended to minimize bleeding risk, according to the European Society of Cardiology guidelines 2

Special Considerations

  • For patients with high thrombotic risk features, considering prolonged DAPT beyond the standard duration is recommended, although this specific recommendation is not provided in the article, a general recommendation for high bleeding risk is to consider shortened DAPT duration (3-6 months) if the PRECISE-DAPT score is ≥25, as suggested by the European Society of Cardiology 2, 5
  • Using validated risk scores to guide duration decisions, such as balancing between thrombotic and bleeding risks, is recommended by the European Society of Cardiology 5
  • Patients with specific high ischemic risk features may require continued P2Y12 inhibitor therapy, as guided by the European Society of Cardiology guidelines 2

Perioperative Management

  • Delaying surgery until completion of the minimum DAPT duration and maintaining aspirin perioperatively if bleeding risk allows is recommended for elective surgery, according to the European Society of Cardiology 2
  • If the patient requires oral anticoagulation, considering shortened DAPT duration and early transition to single antiplatelet plus anticoagulant is recommended, as suggested by the European Society of Cardiology 2
  • Aspirin can typically be continued perioperatively unless bleeding risk is prohibitively high, according to the European Society of Cardiology guidelines 2

Potential Pitfalls

  • Premature discontinuation of antiplatelet therapy increases the risk of thrombotic events, as reported in Circulation 6
  • Failure to consider drug interactions, particularly with PPIs that may reduce clopidogrel efficacy, is a significant concern, as recommended by the European Society of Cardiology 2
  • Unnecessary continuation of DAPT beyond the recommended duration increases bleeding risk without clear ischemic benefit, as warned by the European Society of Cardiology guidelines 2
  • Failure to reassess bleeding and ischemic risks periodically can lead to inadequate management, and these risks can change over time, according to the European Society of Cardiology guidelines 2